EP1786785A2 — Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Assigned to Pfizer Inc · Expires 2007-05-23 · 19y expired
What this patent protects
Enantiomerically pure compound of formula (I) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
USPTO Abstract
Enantiomerically pure compound of formula (I) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
Drugs covered by this patent
- Xalkori (crizotinib) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.